TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$1.62 USD
-0.12 (-6.90%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $1.62 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, TScan Therapeutics, Inc. has a market cap of $98.47M, which represents its share price of $1.74 multiplied by its outstanding shares number of 56.59M. As a small-cap company, TCRX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TCRX 1.62 -0.12(-6.90%)
Will TCRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
Other News for TCRX
Tracking Baker Brothers Portfolio - Q1 2025 Update
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)
Morgan Stanley Keeps Their Buy Rating on TScan Therapeutics (TCRX)
TScan Therapeutics management to meet virtually with BTIG
TCRX: Upcoming Virtual Meeting Scheduled for May 15 | TCRX Stock News